Showing results (61-70 of 162) with videos related to

Sort By:
Pageof 17
Blood Advances|April 9, 2025
Comparative efficacy of Bruton tyrosine kinase inhibitors in high-risk relapsed/refractory CLL: a network meta-analysisMazyar Shadman, Jennifer R Brown, Leyla Mohseninejad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2006
Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemiaMarco Montillo, Alessandra Tedeschi, Sara Miqueleiz, et al.
Leukemia & Lymphoma|September 18, 2015
A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphomaStefano Luminari, Maria Goldaniga, Marina Cesaretti, et al.
Therapeutic Advances in Medical Oncology|July 14, 2025
Efficacy of zanubrutinib versus acalabrutinib for relapsed or refractory chronic lymphocytic leukemia (R/R CLL): a matching-adjusted indirect comparison (MAIC)Mazyar Shadman, Jennifer R Brown, Rhys Williams, et al.
Blood|July 21, 2011
An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemiaMarco Montillo, Alessandra Tedeschi, Valeria Belsito Petrizzi, et al.
Cancer|December 20, 2011
Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas: phase 2 study of the Italian Lymphoma FoundationAndrea Ferrario, Alessandro Pulsoni, Barbara Olivero, et al.
Blood|September 6, 2013
Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)Meletios A Dimopoulos, Ramón García-Sanz, Maria Gavriatopoulou, et al.
Blood|November 23, 2016
BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 yearsMaria Gavriatopoulou, Ramón García-Sanz, Efstathios Kastritis, et al.
The Lancet. Haematology|July 1, 2018
Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart reviewChristian Buske, Shalal Sadullah, Efstathios Kastritis, et al.
Cancer|July 7, 2011
Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced diseaseAlessandra Tedeschi, Giulia Benevolo, Marzia Varettoni, et al.
Pageof 17